Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at William Blair upped their FY2017 earnings estimates for Collegium Pharmaceutical in a report issued on Thursday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of ($2.30) for the year, up from their prior forecast of ($2.80). William Blair also issued estimates for Collegium Pharmaceutical’s Q4 2017 earnings at ($0.34) EPS, Q1 2018 earnings at ($0.44) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($0.99) EPS and FY2019 earnings at $0.22 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The company had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. During the same period in the prior year, the company posted ($1.13) EPS. The firm’s quarterly revenue was up 2814.6% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/14/equities-analysts-set-expectations-for-collegium-pharmaceutical-inc-s-fy2017-earnings-coll.html.

Other research analysts have also issued reports about the company. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Monday. BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. HC Wainwright initiated coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They set a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average target price of $19.33.

Collegium Pharmaceutical (COLL) opened at $14.61 on Monday. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $18.02.

Several hedge funds have recently made changes to their positions in the company. Credit Suisse AG increased its holdings in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after purchasing an additional 1,173 shares during the period. Nationwide Fund Advisors increased its holdings in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 1,422 shares during the period. American International Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,163 shares during the period. Royal Bank of Canada increased its holdings in shares of Collegium Pharmaceutical by 12.7% in the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 3,285 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 3,775 shares during the period. 83.96% of the stock is currently owned by institutional investors and hedge funds.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.